{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:25:46Z","timestamp":1761128746140},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2009,6,10]],"date-time":"2009-06-10T00:00:00Z","timestamp":1244592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6,10]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Flebogamma\u00ae 5% dual inactivation and filtration (DIF), a new 5% liquid intravenous immunoglobulin with a stability of 2 years when stored at temperatures between 2 and 30\u00b0C, has been developed. This new product is the result of the accumulated experience provided by Flebogamma\u00ae, with more than 30 million grams administered since 1992 in Europe and the United States, and the implementation of the latest technology to improve Flebogamma\u00ae even more by increasing its viral safety margin further. In addition to the specific inactivation stage for Flebogamma\u00ae 5% (pasteurization), the new process includes a solvent\u2013detergent treatment and nanofiltration through a Planova filter down to 20\u2003nm. The preparation presents a mean purity of 99\u00b76\u2003\u00b1\u20030\u00b72% with a correct chromatographic profile. Percentage values of immunoglobulin (Ig)G subclasses are equivalent to the physiological values of normal serum. The content in IgA as well as other possible impurities is very low, and the product presents a mean result of 109\u2003\u00b1\u20035% in the Fc fragment functionality assay, demonstrating the integrity of the IgG molecule. The functionality is also reflected in neutralization tests carried out against poliomyelitis, diphtheria, measles and vaccinia which, apart from the antibody titres determined by enzyme-linked immunosorbent assay, guarantees that antibodies are capable of reacting against these pathogens. Regarding safety, the combination of multiple methods with capacity to inactivate or remove biological agents which include chemical inactivation, heat inactivation, nanofiltration and precipitations, with very different mechanisms of action, provides Flebogamma\u00ae 5% DIF very wide margins of safety regarding to potential pathogens.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2009.03953.x","type":"journal-article","created":{"date-parts":[[2009,6,10]],"date-time":"2009-06-10T10:59:33Z","timestamp":1244631573000},"page":"17-21","source":"Crossref","is-referenced-by-count":16,"title":["Flebogamma\u00ae 5% DIF development: rationale for a new option in intravenous immunoglobulin therapy"],"prefix":"10.1093","volume":"157","author":[{"given":"J I","family":"Jorquera","sequence":"first","affiliation":[{"name":"Research and Development Area, Instituto Grifols S.A., Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,6,10]]},"reference":[{"key":"2021122708533273400_b1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/ja01207a034","article-title":"Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids","volume":"68","author":"Cohn","year":"1946","journal-title":"J Am Chem Soc"},{"key":"2021122708533273400_b2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1021\/ja01157a122","article-title":"A system for the separation of the components of human blood: quantitative procedures for the separation of the protein components of human plasma","volume":"72","author":"Cohn","year":"1950","journal-title":"J Amer Chem Society"},{"key":"2021122708533273400_b3","volume-title":"Electrophoresis"},{"key":"2021122708533273400_b4","volume-title":"Immunochemical methods"},{"key":"2021122708533273400_b5","volume-title":"Liquid chromatography"},{"key":"2021122708533273400_b6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal Biochem"},{"key":"2021122708533273400_b7","volume-title":"Test for Fc function of immunoglobulin","author":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding"},{"key":"2021122708533273400_b8","volume-title":"Test of anticomplementary activity of immunoglobulin"},{"key":"2021122708533273400_b9","volume-title":"Prekallikrein activator"},{"key":"2021122708533273400_b10","volume-title":"Anti-A and anti-B haemagglutinins (indirect method)"},{"key":"2021122708533273400_b11","volume-title":"Anti-D antibodies"},{"key":"2021122708533273400_b12","volume-title":"Diagnostic procedures for viral, rickettsial and chlamydial infections","author":"Lennette","year":"1979","edition":"5th"},{"key":"2021122708533273400_b13","first-page":"690","volume-title":"Manual of clinical laboratory immunology","author":"Rose","year":"1997"},{"key":"2021122708533273400_b14","volume-title":"Bacteriolog\u00ede medicale","author":"Dumas","year":"1951"},{"key":"2021122708533273400_b15","volume-title":"Revised CPMP Guideline in Virus validation studies","year":"1995"},{"key":"2021122708533273400_b16","volume-title":"Note for guidance on plasma-derived medicinal products","year":"1995"},{"key":"2021122708533273400_b17","volume-title":"Quality of biotechnological products viral safety evaluation by biotechnology products derived from cell lines of human or animal origin","year":"1995"},{"key":"2021122708533273400_b18","volume-title":"Aplicaciones cl\u00ednicas del tratamiento con inmunoglobulinas intravenosas, Barcelona","author":"Yap","year":"1993"},{"key":"2021122708533273400_b19","first-page":"561","article-title":"Nephelometric measurements of human IgG subclasses and their reference ranges","volume":"52","author":"Vlug","year":"1994","journal-title":"Ann Biol Clin"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2009.03953.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/157\/Supplement_1\/17\/41925318\/j.1365-2249.2009.03953.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/157\/Supplement_1\/17\/41925318\/j.1365-2249.2009.03953.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:21:47Z","timestamp":1641054107000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/157\/Supplement_1\/17\/6438942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,10]]},"references-count":19,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2009,6,10]]},"published-print":{"date-parts":[[2009,6,10]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2009.03953.x","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2009,9]]},"published":{"date-parts":[[2009,6,10]]}}}